

MINUTES

Name of Meeting: Pharmacy Liaison Committee
Date of Meeting: December 1, 2010
Length of Meeting: 10:07 AM – 11:28 AM
Location of Meeting: DMAS 13th Floor Board Room

Meeting Attendees

DMAS Staff:

Bryan Tomlinson, Director Health Care Services
Keith Hayashi, Pharmacist
Tyrone Wall, Compliance Specialist
Donna Francioni-Proffitt, Pharmacy Program Manager
Scott Cannady, Senior Policy Analyst
Maryanne Paccione, Information Systems

Committee Members:

Anne Leigh Kerr, Pharmaceutical Research and Manufacturers of America
Bill Hancock, Long Term Care Pharmacy Coalition
Alexander Macauley, EPIC Pharmacy
Kemper Heyers, Virginia Association of Chain Drug Stores (VACDS)
Tim Musselman, Virginia Pharmacists Association

Other Attendees:

Richard Grossman, Vectre Corporation
Cindy Snyder, GSK
Tyler Cox, Amgen
Rusty Maney, VACDS

Call to Order

November 9, 2009 minutes were approved.

Introduction

Bryan Tomlinson welcomed everyone to the meeting and introduced the new Agency Director, Dr. Gregg Pane.

Dr. Pane graciously thanked the Committee for their work in the past and future endeavors.

New Business

Bryan Tomlinson explained recent efforts to expand MCO markets in other parts of the Commonwealth

Bryan Tomlinson and Dr. Pane asked the members if they had any suggestions or comments.

One committee member wanted to know if medication management could become a payable service if provided by a pharmacist.

Dr. Pane explained how DMAS is exploring grants/funding opportunities from the Federal Government that were included in recent Federal health care reform legislation. The funding for these grants often include a higher share of Federal funds. Some of these grants have a Federal participation percentage of 90% as opposed the standard 50% Federal share for Virginia Medicaid administrative costs.

Comments were provided by members that stressed the importance of Medication Therapy Management and the need for DMAS to implement these types of programs in fee-for-service. Donna Proffitt asked if any of the Committee members have data available that show cost savings on medication therapy management (MTM) that DMAS could review. Mr. Tomlinson pointed out that DMAS would need to show an immediate cost savings with any MTM proposals because these types of programs would initially increase the agency's administrative budget.

Bryan Tomlinson informed the Committee that DMAS has contracted with ACS to become the fiscal agent, claims processor and Drug Utilization Review (DUR) coordinator. Magellan now is contracted to provider (MAC) Maximum Allowable Cost, (SMAC) Specialty Maximum Allowable Cost and (PDL) Preferred Drug List. SXC is the Drug Rebate contractor.

Bryan Tomlinson also informed the Committee that SXC will be invoicing the rebated for the MCOs

Bryan Tomlinson discussed the rollback of Average Wholesale Price (AWP), a pricing formula used to calculate reimbursement for drugs for the Virginia Medicaid program. The AWP Rollback occurred as a result of a court settlement with First DataBank. Mr. Tomlinson indicated that DMAS is still evaluating the impact this change will have on the DMAS pharmacy benefit.

With no other business, Mr. Tomlinson adjourned the meeting at 11:28 a.m.